Recent news on Dacarbazine

Genta Incorporated Announces First Quarter 2007 Financial Results ...  -  May 8, 2007
PR Newswire (press release),New Phase 3 Trial of Genasense plus Dacarbazine in Advanced Melanoma In April, the Company announced a new Phase 3 trial, now known as AGENDA: "A Randomized

CHMP Adopts Negative Opinion on Genasense(R) Application in Melanoma  -  Apr 27, 2007
PR Newswire (press release),The MAA proposes the use of Genasense plus dacarbazine for treatment of patients with advanced melanoma. The Company had previously announced its

SciClone Announces ZADAXIN and SCV-07 Abstracts Accepted at ASCO  -  Apr 27, 2007
PharmaLive.com (press release),A large first-line, randomized, dose-finding, phase II study on Thymosin alpha 1 (T?1) plus Dacarbazine (DTIC) with or without Interferon alpha (IFN?

Genta Announces New Phase 3 Trial of Genasense in Patients with ...  -  Apr 18, 2007
PharmaLive.com (press release),The trial is designed to expand evidence for the safety and efficacy of Genasense combined with dacarbazine for patients who have not previously been

Genta to Begin Genasense Trial  -  Apr 18, 2007
Forbes,The purpose of the trial is to test the safety of Genasense combined with dacarbazine, a chemotherapy drug, for patients not previously treated with

Genta Announces Expectation of a Negative Opinion from the CHMP on ...  -  Apr 5, 2007
Drug Newswire (press release),..."We believe the safety and efficacy results for Genasense plus dacarbazine are superior to any other product ever considered by regulatory authorities for

Current Treatment of Malignant Pheochromocytoma  -  Apr 4, 2007
Journal of Clinical Endocrinology and Metabolism,Similar to cytotoxic chemotherapy with cyclophosphamide, vincristine, and dacarbazine, MIBG can induce remission for a limited period in a significant

Genta Announces New Phase 3 Trial of Genasense(R) in Patients with ...  -  Apr 18, 2007
PR-Inside.com (Pressemitteilung),...to expand evidence for the safety and efficacy of Genasense combined with dacarbazine for patients who have not previously been treated with chemotherapy.

Genta gives Genasense another chance  -  Apr 19, 2007
BiopharmaReporter.com,The trial is designed to expand evidence for the safety and efficacy of Genasense combined with Bayer's dacarbazine (DTIC) - a drug commonly used in the

A LONELY STRUGGLE  -  Apr 5, 2007
Philadelphia Inquirer,He began chemo treatments at Jefferson, receiving an intravenous combination called ABVD, for the drugs Adriamycin, bleomycin, vinblastine and dacarbazine.

Genta Announces Closing of Common Stock Offering  -  Apr 4, 2007
Drug Newswire (press release),Genta has completed a pending Marketing Authorization Application to the European Medicines Agency (EMEA) for use of Genasense plus dacarbazine for

Phase 2 Results Of Genasense(R) Plus Chemotherapy In Advanced ...  -  Feb 24, 2007
Medical News Today (press release),Genta has completed a pending Marketing Authorization Application to the European Medicines Agency (EMEA) for use of Genasense plus dacarbazine for

Genta Incorporated to Host Conference Call to Discuss Fourth ...  -  Feb 7, 2007
PharmaLive.com (press release),Genta has completed a pending Marketing Authorization Application to the European Medicines Agency (EMEA) for use of Genasense plus dacarbazine for

Cancer treatments better but could be 'phenomenal'  -  Feb 23, 2007
Iowa City Press Citizen,Hodgkin's most often is treated with a combination of four drugs: Adriamycin, bleomycin, vinblastine and dacarbazine. A combination of radiation therapy and

Cell Genesys And Medarex Announce Encouraging Follow-Up Results ...  -  Feb 23, 2007
Medical News Today (press release),...as a first-line treatment in combination with dacarbazine, and as a second-line treatment in combination with a melanoma- peptide vaccine.

Cell Genesys and Medarex Announce Encouraging Follow-Up Results ...  -  Feb 22, 2007
PharmaLive.com (press release),...as a first-line treatment in combination with dacarbazine, and as a second-line treatment in combination with a melanoma- peptide vaccine.

Genta Incorporated Announces Fourth Quarter and Year End 2006 ...  -  Feb 13, 2007
Insurance News Net,Genta's Marketing Authorization Application (MAA) for the use of Genasense plus dacarbazine for treatment of patients with advanced melanoma is currently

Genta Completes Response to EMEA List of Outstanding Issues for ...  -  Feb 7, 2007
Drug Newswire (press release),In this trial, which was conducted at 139 sites in 9 countries, 771 patients were randomly assigned to receive chemotherapy with dacarbazine (DTIC) alone or

Pharma Sector: Few Newsmakers Of The Week - Exelixis, MGI Pharma ...  -  Feb 3, 2007
Trading Markets,The company's woes have been confounded by the rejection of its combination therapy of Genasense plus dacarbazine for the treatment of patients with

Pharma Sector: Few Newsmakers Of The Week - Opexa, J&J, Glaxo ...  -  Feb 11, 2007
Trading Markets,In 2004, the FDA advisory panel voted down the use of a combination therapy of Genasense plus dacarbazine for the treatment of patients with advanced

Patients with Hodgkin’s Lymphoma at Risk for Heart Attack Later in ...  -  Feb 16, 2007
Cancer Consultants (press release),...treatment with anthracyclines, vincristine, or the chemotherapy regimen consisting of doxorubicin, bleomycin, vinblastine, and dacarbazine.

Patients with Hodgkin’s at Risk for Heart Attack Later in Life  -  Feb 14, 2007
Cancer Consultants (press release),...with anthracyclines, the chemotherapy agent vincristine, or the chemotherapy regimen consisting of doxorubicin, bleomycin, vinblastine, and dacarbazine.

Hodgkin's Therapy Raises Long-Term MI Risk  -  Feb 7, 2007
MedPage Today,Patients who had received combination chemotherapy with the ABVD regimen -- Adriamycin (doxorubicin), Blenoxane (bleomycin), Oncovin, and dacarbazine

Risk for fatal MI persists 25 years after Hodgkin's treatment  -  Feb 7, 2007
TheHeart.Org,MI risk was particularly high for patients treated with the doxorubicin, bleomycin, vinblastine, and dacarbazine regimen (SMR 9.5; 95% CI 3.5-20.6).

Genta Announces the Company Will Appeal FDA Action on New Drug ...  -  Feb 7, 2007
PipelineReview.com (press release),Genta has also completed a Marketing Authorization Application to the European Medicines Agency (EMEA) for use of Genasense plus dacarbazine for treatment

SciClone Soars on Early Zadaxin Data  -  Dec 22, 2006
Houston Chronicle,The company said the first four groups out of five to be tested in a Phase II clinical trial for Zadaxin showed the cancer drug, when added to dacarbazine

SciClone Surges on Trial Data  -  Dec 22, 2006
TheStreet.comPatients who received the drug plus dacarbazine chemotherapy survived a median 10.2 months, while patients on dacarbazine and the common treatment

SciClone melanoma drug shows promise; shares soar  -  Dec 22, 2006
ReutersIn one arm of the study, a 3.2 mg dose of Zadaxin plus the chemotherapy dacarbazine boosted median survival to 10.2 months, compared with 6.6 months for

Vical Initiates Pivotal Phase 3 Trial Of Allovectin-7(R) As First ...  -  Jan 6, 2007
Medical News Today (press release),The toxicity associated with FDA-approved treatments such as dacarbazine or interleukin-2 is often significant, resulting in serious or life-threatening

SciClone Climbs On Phase II Zadaxin Data In Skin Cancer  -  Dec 22, 2006
BioWorld Online,Interim results show that the addition of 3.2 mg of Zadaxin (thymalfasin) to dacarbazine (DTIC) chemotherapy increased the median survival to 10.2 months vs

Medarex Announces Enrollment Complete In Ipilimumab (MDX-010 ...  -  Jan 6, 2007
Medical News Today (press release),...as a first-line treatment in combination with dacarbazine, and as a second-line treatment in combination with a melanoma-peptide vaccine.

SciClone Pharmaceuticals Rose On Positive Phase II News  -  Dec 22, 2006
Trading Markets,Data from the first four arms of this ongoing five-arm trial showed that the addition of 3.2 mg of ZADAXIN to standard dacarbazine (DTIC | charts | news

SciClone and Sigma-Tau Announce Positive Interim Survival Data ...  -  Dec 22, 2006
PharmaLive.com (press release),...of 3.2 mg of ZADAXIN(r) (thymalfasin or thymosin alpha 1) to standard dacarbazine (DTIC) chemotherapy increased the median survival to 10.2 months.

SciClone and Sigma-Tau Announce Positive Interim Survival Data ...  -  Dec 22, 2006
Market Wire (press release)...of 3.2 mg of ZADAXIN® (thymalfasin or thymosin alpha 1) to standard dacarbazine (DTIC) chemotherapy increased the median survival to 10.2 months.

Genta Restructures Operations to Focus on Future Initiatives  -  Dec 20, 2006
Drug Newswire (press release),Genta has completed a pending Marketing Authorization Application to the European Medicines Agency (EMEA) for use of Genasense plus dacarbazine for

SciClone Soars on Early Zadaxin Data  -  Dec 22, 2006
Houston Chronicle,The company said the first four groups out of five to be tested in a Phase II clinical trial for Zadaxin showed the cancer drug, when added to dacarbazine

SciClone Surges on Trial Data  -  Dec 22, 2006
TheStreet.comPatients who received the drug plus dacarbazine chemotherapy survived a median 10.2 months, while patients on dacarbazine and the common treatment

SciClone melanoma drug shows promise; shares soar  -  Dec 22, 2006
ReutersIn one arm of the study, a 3.2 mg dose of Zadaxin plus the chemotherapy dacarbazine boosted median survival to 10.2 months, compared with 6.6 months for

Genta Initiates Pilot Clinical Trial of Genasense® Plus Abraxane ...  -  Nov 30, 2006
PipelineReview.com (press release),This trial is the first follow-on study to Genta's randomized Phase 3 trial of Genasense plus dacarbazine that showed benefit across multiple clinical

Medarex Announces FDA Fast Track Designations for Ipilimumab for ...  -  Dec 7, 2006
DG NewsProtocol Assessment agreements with the FDA for the treatment of metastatic melanoma -- as a first-line treatment in combination with dacarbazine,

SciClone Climbs On Phase II Zadaxin Data In Skin Cancer  -  Dec 22, 2006
BioWorld Online,Interim results show that the addition of 3.2 mg of Zadaxin (thymalfasin) to dacarbazine (DTIC) chemotherapy increased the median survival to 10.2 months vs

Medarex Gets Ipilimumab FDA Fast Track  -  Dec 7, 2006
Forbes,The designation is for the use of ipilimumab, also known as MDX-010, as a therapy in combination with the chemotherapy dacarbazine in previously untreated

Nexavar in patients with advanced melanoma does not meet primary ...  -  Dec 6, 2006
Xagena.it,Two hundred seventy patients progressing after one previous systemic chemotherapeutic treatment ( with either Dacarbazine or Temozolomide ) were enrolled

Pharma Sector: Few Newsmakers Of The Week - Teva, Barr, Genta ...  -  Dec 1, 2006
Trading Markets,However, patients treated with Genasense plus dacarbazine showed a significant increase in progression-free survival, compared to patients treated with

Onyx Pharmaceuticals (ONXX) Provides Update for Phase II Studies ...  -  Dec 18, 2006
StreetInsider.com (subscription),The Phase II study in chemo-naive melanoma patients compared Nexavar in combination with dacarbazine (DTIC) versus placebo in combination with DTIC.

SciClone Pharmaceuticals Rose On Positive Phase II News  -  Dec 22, 2006
Trading Markets,Data from the first four arms of this ongoing five-arm trial showed that the addition of 3.2 mg of ZADAXIN to standard dacarbazine (DTIC | charts | news

SciClone and Sigma-Tau Announce Positive Interim Survival Data ...  -  Dec 22, 2006
PharmaLive.com (press release),...of 3.2 mg of ZADAXIN(r) (thymalfasin or thymosin alpha 1) to standard dacarbazine (DTIC) chemotherapy increased the median survival to 10.2 months.

SciClone and Sigma-Tau Announce Positive Interim Survival Data ...  -  Dec 22, 2006
Genetic Engineering News (press release),...of 3.2 mg of ZADAXIN(R) (thymalfasin or thymosin alpha 1) to standard dacarbazine (DTIC) chemotherapy increased the median survival to 10.2 months.

SciClone and Sigma-Tau Announce Positive Interim Survival Data ...  -  Dec 22, 2006
Market Wire (press release)...of 3.2 mg of ZADAXIN® (thymalfasin or thymosin alpha 1) to standard dacarbazine (DTIC) chemotherapy increased the median survival to 10.2 months.

Genta Restructures Operations to Focus on Future Initiatives  -  Dec 20, 2006
Drug Newswire (press release),Genta has completed a pending Marketing Authorization Application to the European Medicines Agency (EMEA) for use of Genasense plus dacarbazine for

Genasense Not Approvable' In CLL; Europe's Ruling Next  -  Dec 15, 2006
BioWorld Online,...the European Medicines Agency and expects word on whether marketing clearance will be granted to Genasense (oblimersen) plus dacarbazine for melanoma.

Ipilimumab (MDX-010) Safety and Clinical Response Data in ...  -  Dec 12, 2006
PipelineReview.com (press release),...as a first-line treatment in combination with dacarbazine, and as a second-line treatment in combination with a melanoma- peptide vaccine.

Genasense(R) Trial in Chronic Lymphocytic Leukemia Shows ...  -  Dec 11, 2006
Drug Newswire (press release),Genta has also completed a Marketing Authorization Application to the European Medicines Agency (EMEA) for use of Genasense plus dacarbazine for treatment

Medarex Announces FDA Fast Track Designations and Biogen Idec to ...  -  Dec 8, 2006
Financial News USA (press release),...(also known as MDX- 010) used in combination with chemotherapy (dacarbazine) in previously untreated (first-line) metastatic melanoma patients.

Onyx/Bayer: to pursue development of Nexavar despite study failure  -  Dec 5, 2006
Pharmaceutical Business Review...who had progressed after one prior chemotherapy regimen containing either the standard agent dacarbazine or Schering-Plough's Temodar (temozolomide).

Onyx Plunges as Study Disappoints  -  Dec 4, 2006
TheStreet.comThe trial enrolled 270 patients whose disease progressed after previous treatments with either dacarbazine or temozolomide chemotherapies.

Phase III Trial of Nexavar in Patients with Advanced Melanoma Does ...  -  Dec 5, 2006
PipelineReview.com (press release),Two hundred seventy patients progressing after one previous systemic chemotherapeutic treatment (with either dacarbazine (DTIC) or temozolomide) were

Onyx's Shares Drop On Top-Line Results Of Nexavar In Melanoma  -  Dec 4, 2006
BioWorld Online,...and placebo-controlled, and involved 270 patients that were progressing in disease after one previous treatment with either dacarbazine or temozolomide.

Genasense(R) Shown Active using Intermittent Dosing in Melanoma ...  09 Nov 2006
Genta has also completed a Marketing Authorization Application to the European Medicines Agency (EMEA) for use of Genasense plus dacarbazine for treatment of ... -Yahoo! News (press release) Neulasta® Safe and Effective for Hodgkin’s Patients Treated ...  Nov 7, 2006
Among Hodgkin’s lymphoma patients treated with ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) chemotherapy every two weeks, use of Neulasta ... -Cancer Consultants (press release), Pharma Sector - Few Newsmakers Of The Week: Tercica, Adherex ...  Nov 4, 2006
In 2004, the FDA advisory panel voted down the use of a combination therapy of Genasense plus dacarbazine for the treatment of patients with advanced melanoma ... -Trading Markets, More Radiotherapy Is Not Better for Elderly Patients with Hodgkin ...  Nov 3, 2006
...lymphoma treated with 20 Gy or 30 Gy of involved field radiation and 2 or 4 cycles of ABVD (doxorubicin, bleomycin, vinblastine and dacarbazine) had equivalent ... -Cancer Consultants (press release), Genasense(R) Receives Orphan Drug Designation in Australia for ...  Oct 17, 2006
..."The recently published Phase 3 study of Genasense plus dacarbazine included a large number of Australian participants and showed benefit across an array of ... -PR Newswire (press release), Genta Gets Orphan Drug Designation In Australia For Genasense ...  Oct 17, 2006
Situated in Berkeley Heights, New Jersey, Genta said that its recently published Phase 3 study of Genasense plus dacarbazine included a large number of ... -Trading Markets, Genta's Gentasense gets orphan status  Oct 17, 2006
..."The recently published phase 3 study of Genasense plus dacarbazine included a large number of Australian participants and showed benefit across an array of ... -United Press International Genta's Advanced Melanoma Drug, Genasense, Granted Orphan Drug ...  Oct 17, 2006
In addition, Genta has filed a Marketing Authorization Application with the European Medicines Agency, for the use of Genasense plus dacarbazine for treatment ... -Trading Markets, Addition of Genasense® to DTIC-Dome® Improves Outcomes in ...  Oct 10, 2006
Results from a multi-national phase III trial indicate that addition of the Genasense® (oblimersen) to DTIC-Dome (dacarbazine) provides a significant survival ... -Cancer Consultants (press release), Ipilimumab (MDX-010) Safety and Clinical Response Data in ...  -  12 Dec 2006
PipelineReview.com (press release),...as a first-line treatment in combination with dacarbazine, and as a second-line treatment in combination with a melanoma- peptide vaccine.

Medarex Announces FDA Fast Track Designations for Ipilimumab for ...  -  Dec 7, 2006
DG NewsProtocol Assessment agreements with the FDA for the treatment of metastatic melanoma -- as a first-line treatment in combination with dacarbazine,

Medarex Gets Ipilimumab FDA Fast Track  -  Dec 7, 2006
Forbes,The designation is for the use of ipilimumab, also known as MDX-010, as a therapy in combination with the chemotherapy dacarbazine in previously untreated

Genta Initiates Pilot Clinical Trial of Genasense® Plus Abraxane ...  -  Nov 30, 2006
PipelineReview.com (press release),This trial is the first follow-on study to Genta's randomized Phase 3 trial of Genasense plus dacarbazine that showed benefit across multiple clinical

Nexavar in patients with advanced melanoma does not meet primary ...  -  Dec 6, 2006
Xagena.it,Two hundred seventy patients progressing after one previous systemic chemotherapeutic treatment ( with either Dacarbazine or Temozolomide ) were enrolled

Genasense(R) Trial in Chronic Lymphocytic Leukemia Shows ...  -  Dec 11, 2006
Drug Newswire (press release),Genta has also completed a Marketing Authorization Application to the European Medicines Agency (EMEA) for use of Genasense plus dacarbazine for treatment

Pharma Sector: Few Newsmakers Of The Week - Teva, Barr, Genta ...  -  Dec 1, 2006
Trading Markets,However, patients treated with Genasense plus dacarbazine showed a significant increase in progression-free survival, compared to patients treated with

Genta Provides Update On Analysis Of Phase 3 Trial Of Genasense(R ...  -  Dec 9, 2006
Medical News Today (press release),Genta has also completed a Marketing Authorization Application to the European Medicines Agency (EMEA) for use of Genasense plus dacarbazine for treatment

Medarex Announces FDA Fast Track Designations and Biogen Idec to ...  -  Dec 8, 2006
Financial News USA (press release),...(also known as MDX- 010) used in combination with chemotherapy (dacarbazine) in previously untreated (first-line) metastatic melanoma patients.

Onyx/Bayer: to pursue development of Nexavar despite study failure  -  Dec 5, 2006
Pharmaceutical Business Review...who had progressed after one prior chemotherapy regimen containing either the standard agent dacarbazine or Schering-Plough's Temodar (temozolomide).

Onyx's Shares Drop On Top-Line Results Of Nexavar In Melanoma  -  Dec 4, 2006
BioWorld Online,...and placebo-controlled, and involved 270 patients that were progressing in disease after one previous treatment with either dacarbazine or temozolomide.

Phase III Trial of Nexavar in Patients with Advanced Melanoma Does ...  -  Dec 4, 2006
PR Newswire (press release),Two hundred seventy patients progressing after one previous systemic chemotherapeutic treatment (with either dacarbazine (DTIC) or temozolomide) were

Onyx Plunges as Study Disappoints  -  Dec 4, 2006
TheStreet.comThe trial enrolled 270 patients whose disease progressed after previous treatments with either dacarbazine or temozolomide chemotherapies.

Genta Incorporated Announces Second Quarter 2006 Financial Results ...  Aug 8, 2006
...with the European Medicines Agency (EMEA) regarding its Marketing Authorization Application (MAA) for the use of Genasense plus dacarbazine as treatment for ... -PR Newswire

Genta Revises Notice Of Special Protocol Assessment For ...  Aug 19, 2006
Genta has also completed a Marketing Authorization Application to the European Medicines Agency (EMEA) for use of Genasense plus dacarbazine for treatment of ... -Medical News Today

TEMODAL(R) Approved By Japan's Ministry of Health, Labor and ...  Jul 31, 2006
TEMODAR Capsules are contraindicated in patients who have a history of hypersensitivity to any of its components, or to dacarbazine (DTIC). ... -International News Service

Temodar® and Peg-Intron® Active in Metastatic Melanoma  Jul 27, 2006
Metastatic melanoma is an incurable disease. For several years the primary drug used for palliation was DTIC®Dome (dacarbazine). ... -Cancer Consultants

Genta Announces Resignation of Jerome Groopman, MD from the Board ...  22 Jul 2006
Genta has also completed a Marketing Authorization Application to the European Medicines Agency (EMEA) for use of Genasense plus dacarbazine for treatment of ... -Yahoo! News

Nexavar Receives FDA Fast Track Designation For Skin Cancer  Jul 21, 2006
Approximately 250 patients with disease progression following one previous systemic chemotherapeutic treatment (with either dacarbazine (DTIC) or temozolomide ... -Medical News Today

Multiferon(R) Article Published In Leading Cancer Journal; Reports ...  Jun 21, 2006
The article, entitled "Long-term survival benefit after adjuvant treatment of cutaneous melanoma with dacarbazine and low dose natural interferon alpha ... -Medical News Today

Special Protocol Assessment for Ipilimumab in Melanoma  Jun 30, 2006
...initiation of a registrational clinical trial evaluating ipilimumab (MDX-010) for use as first-line treatment, in combination with dacarbazine, for metastatic ... -Cancer Consultants

New Orphan Drug Indication for Amplimexon™  Jun 30, 2006
Amplimexon is currently in phase I-II studies evaluating its effectiveness in combination with dacarbazine for the treatment of melanoma, and Gemzar ... -Cancer Consultants

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional